Stockreport

Can-Fite Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study

Can-Fite Biopharma Ltd Sponsored ADR (Israel)  (CANF) 
NASDAQ:AMEX Investor Relations: ir.canfite.com
PDF Namodenoson showed efficacy in pre-clinical models via a definitive molecular mechanism of action PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE [Read more]